Kyntra Bio, Inc. (BMV:KYNB)
Mexico · Delayed Price · Currency is MXN | Market Cap | 516.04M -35.3% |
| Revenue (ttm) | 115.94M -78.3% |
| Net Income | 3.30B |
| EPS | 816.90 |
| Shares Out | n/a |
| PE Ratio | 0.16 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 108 |
| Average Volume | 438 |
| Open | 119.99 |
| Previous Close | n/a |
| Day's Range | 119.99 - 119.99 |
| 52-Week Range | 105.00 - 225.00 |
| Beta | n/a |
| RSI | 32.59 |
| Earnings Date | Feb 23, 2026 |
About Kyntra Bio
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United ... [Read more]
News
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and rema...
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 aft...
What's Going On With Kyntra Bio Stock Tuesday?
Kyntra Bio Inc. (NASDAQ: KYNB), formerly Fibrogen, shares fluctuated in Tuesday's premarket session as the company announced data from a Phase 1b/2 study of FG-3246 in combination with enzalutamide fo...
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the data on anti-tumor activity of FG-3246 in combination with enzalu...
Kyntra Bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company's management will participate in the following investor c...
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it is rebranding the company to Kyntra Bio, representing the next step of the transformation of the Comp...
FibroGen to Report Third Quarter 2025 Financial Results
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct ...
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-clas...
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Co...
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Ho...
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2025 and provided an update on the company's recent developments.
FibroGen to Report Second Quarter 2025 Financial Results
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also cond...
Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 500 points on Friday.
FibroGen Announces 1-for-25 Reverse Stock Split
SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Revers...
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2025 and provided an update on the company's recent developments.
Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)
Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehens...
FibroGen to Report First Quarter 2025 Financial Results
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a...
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place Ap...
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2024 and provided an update on the company's recen...
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen ...
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
FibroGen Inc. FGEN stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc AZN for approximately $160 million.
FibroGen sells China unit to AstraZeneca in deal worth $160 million
FibroGen said on Thursday that it has sold its China unit to AstraZeneca for about $160 million.
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.
FibroGen Appoints David DeLucia as Chief Financial Officer
SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The compa...